Obinutuzumab

證據等級: L5

預測適應症: 3 個

Note on indication selection: predicted_indications[0] and [1] (CLL/SLL variants, TxGNN score 99.21%) both carry zero clinical-trial or literature records in this dataset (L5/Hold), and the evidence pack itself flags this as a likely data-collection gap rather than a true absence of evidence (Obinutuzumab/Gazyva is publicly known to be approved for CLL elsewhere). Since those two entries cannot be substantiated from the data provided, this report is built around predicted_indications[2] — Follicular Lymphoma, the only candidate in this pack with real trial/literature support (L1, "Proceed with Guardrails"). The CLL/SLL anomaly is flagged separately below rather than silently dropped.

Obinutuzumab: From Anti-CD20 Antibody Therapy to Follicular Lymphoma

One-Sentence Summary

Obinutuzumab is a glycoengineered type II anti-CD20 monoclonal antibody; this evidence pack contains no confirmed local original-indication or market record for the drug (currently not marketed in this jurisdiction). The TxGNN model predicts it may be effective for Follicular Lymphoma, with 50 clinical trials and 20 publications identified during evidence collection — of which the 10 most relevant of each are summarized below.

Quick Overview

Item	Content
Original Indication	Not available — no approved indication on file; the drug is not currently marketed in this jurisdiction
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.18%
Evidence Level	L1
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Data-quality note: The same evidence pack also ranks "CLL/SLL with IGHV somatic hypermutation" (score 99.21%) and "pregerminal-center CLL/SLL" (score 99.21%) as the top two TxGNN predictions, but both have 0 matched clinical trials and 0 literature records (Evidence Level L5, Decision: Hold). The evidence pack's own rationale text explicitly notes this conflicts with the publicly known fact that Obinutuzumab is approved for CLL in multiple countries, and recommends verifying the data source before making any decision on those two indications. They are not further analyzed in this report and should be re-queried rather than treated as true negatives.

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not present in the structured original_moa field of this evidence pack (marked as a data gap). However, the supporting literature captured in the evidence base consistently describes Obinutuzumab as a recombinant, humanized, glycoengineered type II anti-CD20 monoclonal antibody (e.g., PMID 28324270, PMID 31360086) that enhances antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct B-cell killing more potently than first-generation anti-CD20 antibodies such as rituximab.

Follicular lymphoma is a germinal-center B-cell-derived indolent lymphoma whose malignant cells characteristically express CD20 on their surface — the same target class that anti-CD20 antibodies (rituximab, obinutuzumab, ofatumumab) already treat in other B-cell malignancies. This gives the TxGNN prediction strong biological plausibility even before considering trial data: it links a known drug target (CD20) to a disease defined by that target's expression.

Critically, this is not a purely computational prediction — it is corroborated by an unusually large and mature body of direct clinical evidence, including the pivotal Phase 3 GALLIUM trial (PMID 28976863, 29856692, 37404773), which directly compared obinutuzumab-based immunochemotherapy against rituximab-based immunochemotherapy in previously untreated follicular lymphoma and demonstrated superior progression-free survival. This makes follicular lymphoma the strongest-supported repurposing candidate in this evidence pack, in contrast to the two CLL/SLL predictions above, which currently have no matched evidence in this dataset.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06191744	Phase 3	Recruiting	1095	EPCORE™FL-2: epcoritamab + lenalidomide/rituximab vs. chemoimmunotherapy in previously untreated FL
NCT05929222	Phase 3	Recruiting	190	GAZEBO trial: radiotherapy alone vs. radiotherapy + obinutuzumab in early-stage FL
NCT05100862	Phase 3	Recruiting	780	Zanubrutinib + anti-CD20 antibody vs. lenalidomide + rituximab in relapsed/refractory FL/MZL
NCT03332017	Phase 2	Completed	217	Zanubrutinib + obinutuzumab vs. obinutuzumab monotherapy in relapsed/refractory FL (ROSEWOOD)
NCT02871219	Phase 2	Completed	96	Obinutuzumab + lenalidomide in previously untreated FL (Grade 1-3a, Stage II-IV)
NCT01582776	Phase 1b/2	Completed	317	Obinutuzumab + lenalidomide across untreated and relapsed/refractory FL and other B-cell lymphomas
NCT04450173	Phase 2	Active, not recruiting	40	Obinutuzumab + ibrutinib + venetoclax in previously untreated FL
NCT03817853	Phase 4	Completed	114	Obinutuzumab short-duration infusion safety in previously untreated advanced FL
NCT05899621	N/A (real-world)	Recruiting	332	Real-world efficacy/safety of obinutuzumab-based therapy in previously untreated FL
NCT06108232	Phase 2	Active, not recruiting	33	Obinutuzumab + CC-99282 in previously untreated, high tumor-burden FL

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28976863	2017	RCT	The New England Journal of Medicine	Pivotal GALLIUM trial: obinutuzumab- vs. rituximab-based chemotherapy in previously untreated advanced-stage FL
29856692	2018	RCT	Journal of Clinical Oncology	GALLIUM sub-analysis: influence of chemotherapy backbone (CHOP/CVP/bendamustine) on efficacy and safety
37404773	2023	RCT	HemaSphere	GALLIUM final analysis: durable PFS benefit of obinutuzumab vs. rituximab immunochemotherapy in FL/MZL
37506346	2023	RCT	Journal of Clinical Oncology	ROSEWOOD: zanubrutinib + obinutuzumab vs. obinutuzumab monotherapy in relapsed/refractory FL
31296423	2019	RCT	The Lancet Haematology	GALEN study: obinutuzumab + lenalidomide in relapsed/refractory follicular B-cell lymphoma
37767550	2024	RCT	Haematologica	Polatuzumab vedotin + bendamustine/rituximab or obinutuzumab in relapsed/refractory FL (Phase Ib/II)
31360086	2017	Review	Blood and Lymphatic Cancer: Targets and Therapy	Overview of obinutuzumab activity alone and in combination in FL
28324270	2017	Review	Targeted Oncology	Review of obinutuzumab in rituximab-refractory/relapsed FL, incl. GADOLIN study
38660754	2024	Review	Turkish Journal of Haematology	Comprehensive review of staging, prognosis, and treatment options in FL
39830356	2024	Review	Frontiers in Pharmacology	Rapid review of efficacy, safety, and cost-effectiveness of obinutuzumab in FL

Germany Market Information

No authorization records are available — taiwan_regulatory.market_status is "未上市" (Not Marketed) with 0 total licenses on file. Obinutuzumab currently has no registered product entry in this jurisdiction's regulatory database.

Cytotoxicity

Obinutuzumab is an antineoplastic agent (CD20-targeted monoclonal antibody used in B-cell malignancies including follicular lymphoma), so this section applies.

Item	Content
Cytotoxicity Classification	Targeted therapy / Immunotherapy (anti-CD20 monoclonal antibody) — not conventional cytotoxic chemotherapy
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted association between Obinutuzumab and follicular lymphoma is supported by a strong CD20-targeted mechanistic rationale and a mature evidence base including a pivotal Phase 3 RCT (GALLIUM) plus multiple completed and ongoing Phase 2/3 trials — meeting the L1 evidence threshold. However, the drug is currently unregistered/not marketed in this jurisdiction, and core safety, MOA, and regulatory data remain unconfirmed, so progression should proceed only with additional safeguards.

To proceed, the following is needed:

Confirm mechanism-of-action and DrugBank category data (currently marked as a data gap, DG002)
Obtain and parse the TFDA/local package insert for warnings, contraindications, and DDI data (currently marked as a blocking data gap, DG001)
Verify local market registration pathway status, since 0 authorizations are currently on file
Re-query the data source for the two CLL/SLL predictions (ranks 1–2) to resolve the apparent evidence-collection gap flagged above before any decision is made on those indications
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.